DI-1859
Based on 2 publication(s) in Google Scholar
DI-1859 is a DCN1 and cullin 3 inhibitor with a Ki of <1 nM against human DCN1. DI-1859 forms a covalent bond with Cys115 of DCN1, cleaves its dimethylamino group, disrupts the DCN1-UBC12 interaction, and selectively inhibits the neddylation modification of cullin 3 relative to other cullins. DI-1859 inactivates CRL3, promotes the accumulation of NRF2 and SLC7A11, upregulates the expression of HO-1 and NQO1, reduces reactive oxygen species (ROS) levels, enhances insulin signaling, promotes insulin secretion, activates RhoA, regulates the phosphorylation of AKT, without completely blocking the neddylation modification of cullin 3 or restoring the expression of IRS-1. DI-1859 can be used in the research of Acetaminophen (HY-66005)-induced hepatotoxicity, hyperglycemia, metabolic dysfunction-associated steatotic liver disease, insulin resistance, breast cancer and lung cancer.
For research use only. We do not sell to patients.
- Purity : 99.62%
- CAS No.: 2247061-09-0
- Formula: C30H45N5O3S
- Molecular Weight:555.78
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) DI-1859
More
Biological Activity
Description
|
DCN1 <1 nM (Ki) |
cullin 3 |
Akt |
CRL3 |
Nrf2 |
SLC7A11 |
HO-1 |
NQO1 |
RhoA |
In Vitro
DI-1859 (1.2-fold molar excess relative to DCN1; 10 min) forms a covalent complex with 100% of recombinant human DCN1 protein within 10 minutes via a reaction that cleaves its dimethylamino group[1].
DI-1859 (1:1.2 protein-to-compound molar ratio; overnight) forms a covalent bond with Cys115 of recombinant human DCN1, with cleavage of its dimethylamino group, and maintains similar noncovalent interactions with DCN1 as the parent compound DI-591[1].
DI-1859 (1.2-fold molar excess relative to DCN3; 180 min) shows no detectable covalent reactivity with recombinant human DCN3 protein after 3 hours of incubation, demonstrating specificity for DCN1[1].
DI-1859 (250-500 nM; 1-2 h) selectively inhibits Cul3 neddylation, stabilizes IRS1 protein, and enhances insulin-stimulated AKT phosphorylation in AML12 mouse hepatocytes[2].
DI-1859 (250 nM; 1 h) inhibits Cul3 neddylation, stabilizes IRS1 protein, and enhances insulin-stimulated AKT phosphorylation in differentiated C2C12 mouse myotubes[2].
DI-1859 (100 nM; 1-3 h) potentiates glucose-stimulated insulin secretion in INS-1 832/13 rat pancreatic β cells via RhoA activation and cytoskeleton remodeling, as evidenced by the loss of effect when RhoA or F-actin dynamics are inhibited[2].
DI-1859 (0.3-10000 nM; 24 h) potently and selectively inhibits cullin 3 neddylation (with >1000-fold selectivity over other cullins) in U2OS, THLE2, MDA-MB-231, KYSE70, and HCT116 cells at concentrations as low as 0.3 nM, leading to accumulation of the CRL3 substrate NRF2 and upregulation of HO-1[1].
DI-1859 (100 nM; 1 h) selectively inhibits Cul3 neddylation and potentiates glucose-stimulated insulin secretion in INS-1 832/13 rat pancreatic β cells[2].
DI-1859 inhibits Cul3 neddylation and increases insulin secretion under both basal (3.5 mM) and glucose-stimulated (10 mM) conditions in cultured human pancreatic islets[2].
DI-1859 (100 nM; 1-2 h) does not promote glycolytic flux or overall glycolysis activity in INS-1 832/13 rat pancreatic β cells[2].
DI-1859 (All tested concentrations; 16 h) produces only modest restoration of insulin signaling via incomplete inhibition of CUL3 neddylation in H118Y SUN1-expressing Huh7 cells[3].
DI-1859 (1-3 μM; 24 h) causes dose-dependent accumulation of SLC7A11 protein in BT549, MCF7, T47D, and H358 cancer cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Osteosarcoma U2OS cells, immortalized THLE2 liver cells, breast cancer MDA-MB-231 cells, esophageal cancer KYSE70 cells, colon cancer HCT116 cells
-
Concentration:0.3-100 nM
-
Incubation Time:24 h
-
Result:Significantly reduced neddylated cullin 3 levels at concentrations as low as 0.3 nM, with profound inhibition achieved at 1-3 nM.
Was >300 times more potent than DI-591 across all tested cell lines.
Was ~30 times more potent than MLN4924 in THLE2 cells.
Had no effect on neddylation of cullin 1, 2, 4A, 4B, or 5 at concentrations up to 1000 nM.
Induced significant accumulation of NRF2 (a CRL3 substrate) at concentrations as low as 0.3-1 nM.
Dose-dependently upregulated HO-1 protein.
Had no effect on CRL1 substrates p21 and BIM, or CRL4A substrate CDT1 at concentrations up to 100 nM.
-
Cell Line:AML12 mouse hepatocytes
-
Concentration:250 nM (pre-incubation for insulin stimulation); 250-500 nM (Cul3 neddylation analysis)
-
Incubation Time:1 h (pre-incubation followed by 0-8 h insulin stimulation); 2 h (Cul3 neddylation analysis)
-
Result:Selectively inhibited Cul3 neddylation without affecting Cul1, Cul2, or Cul4B neddylation in cells treated for 2 hours.
Stabilized IRS1 protein in serum/ITS-starved cells pre-treated with 250 nM DI-1859.
Enhanced and prolonged insulin-stimulated AKT phosphorylation (S473) compared to vehicle-treated cells over 8 hours of insulin stimulation.
-
Cell Line:differentiated C2C12 mouse myotubes
-
Concentration:250 nM
-
Incubation Time:1 h (pre-incubation followed by 0-8 h insulin stimulation)
-
Result:Inhibited Cul3 neddylation in C2C12 myotubes over 8 hours of insulin stimulation.
Stabilized IRS1 protein in C2C12 myotubes over 8 hours of insulin stimulation.
Enhanced and prolonged insulin-stimulated AKT phosphorylation (S473) compared to vehicle-treated cells over 8 hours of insulin stimulation.
-
Cell Line:Huh7 cells stably expressing H118Y SUN1-mCherry, parental Huh7 cells, WT Huh7 cells
-
Concentration:All tested concentrations
-
Incubation Time:16 h
-
Result:Did not completely block CUL3 neddylation or restore IRS-1 expression in H118Y SUN1-expressing Huh7 cells.
Produced only a modest increase in insulin-stimulated AKT Ser473 phosphorylation in H118Y SUN1-expressing Huh7 cells.
Showed persistent CUL3 neddylation at all tested concentrations in WT, H118Y SUN1-expressing, and parental Huh7 cells.
-
Cell Line:BT549, MCF7, T47D, H358
-
Concentration:1-3 μM
-
Incubation Time:24 h
-
Result:Caused dose-dependent accumulation of SLC7A11 protein across all tested cell lines.
In Vivo
DI-1859 (50 mg/kg; i.p.; daily; 14 days) shows no toxicity in C57BL/6 male mice[1].
DI-1859 (25-50 mg/kg; i.p.; once daily; 3 days) effectively protects against Acetaminophen (HY-66005)-induced liver toxicity in C57BL/6 male mice, with 50 mg/kg providing near-complete protection in the prevention setting and both doses reducing ALT elevation by ~50% in the treatment setting[1].
DI-1859 (10 mg/kg; i.p.; single dose) significantly lowers blood glucose, increases blood insulin and c-peptide, and improves glucose tolerance in Western diet-induced obese male C57BL/6J mice[2].
DI-1859 (10 mg/kg; i.p.; single dose) fails to lower blood glucose in streptozotocin-induced insulin-deficient diabetic male C57BL/6J mice, confirming its glucose-lowering effect is insulin-dependent[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, ~8 weeks old)[1]
-
Dosage:25 mg/kg
-
Administration:i.p.; single dose
-
Result:Induced robust upregulation of NRF2 protein in mouse liver, with the effect persisting for >24 hours.
-
Animal Model:C57BL/6 (male, ~8 weeks old, acetaminophen-induced liver toxicity model)[1]
-
Dosage:25 mg/kg; 50 mg/kg
-
Administration:i.p.; once daily; 3 days
-
Result:Reduced acetaminophen-induced serum ALT elevation by 20% at 24 hours, largely abolished tissue distortion, and reduced liver damage at 25 mg/kg in prevention setting.
Reduced acetaminophen-induced serum ALT elevation by 90% at 24 hours and nearly completely prevented liver tissue damage at 50 mg/kg in prevention setting.
Reduced liver reactive oxygen species (ROS) levels at both doses in prevention setting.
Reduced acetaminophen-induced serum ALT elevation by ~50% at 24 hours, significantly reduced liver tissue damage, and lowered liver ROS levels at both 25 mg/kg and 50 mg/kg in treatment setting.
-
Animal Model:C57BL/6 (male, ~8 weeks old)[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; daily; 14 days
-
Result:Was well tolerated, with no changes in body weight, organ weights, hematologic parameters, or observable tissue damage in liver, heart, kidney, lung, intestine, stomach, pancreas, colon, or spleen compared to vehicle-treated mice.
-
Animal Model:C57BL/6J (male, Western diet-induced obese)[2]
-
Dosage:10 mg/kg
-
Administration:i.p.; single dose
-
Result:Significantly decreased blood glucose (p<0.05).
Elevated blood insulin (p<0.05).
Elevated c-peptide (p<0.05).
Improved glucose tolerance relative to vehicle control.
-
Animal Model:C57BL/6J (male, streptozotocin-induced diabetic); C57BL/6J (male, non-diabetic control)[2]
-
Dosage:10 mg/kg
-
Administration:i.p.; single dose
-
Result:Did not significantly alter blood glucose levels in streptozotocin-induced diabetic mice.
Did not significantly alter insulin levels in streptozotocin-induced diabetic mice.
Significantly decreased blood glucose in non-diabetic control mice.
Significantly increased blood insulin in non-diabetic control mice.
Chemical Information
-
CAS No. 2247061-09-0
-
Appearance Solid
-
Molecular Weight 555.78
-
Formula C30H45N5O3S
-
Color White to off-white
-
SMILES
CN(C)CC(C(NC[C@H](C1CCCCC1)NC([C@@H](NC(CC)=O)CC(SC2=C3)=NC2=CC=C3C(C)C)=O)=O)=C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2026 Apr 29. PMID: 42056084 -
bioRxiv
The inner nuclear membrane protein SUN1 regulates cullin-3 neddylation to maintain insulin signaling. [Abstract]2026 Apr 20:2026.04.16.718478. PMID: 42079055
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (179.93 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Human Islet Cell Culture
The method of preserving islets in vitro, with purified reduced immunogenicity. The steps are islet isolation, islet cell purification, in vitro determination of islet function and islet cell culture.
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Hepatotoxicity Study
This protocol evaluates hepatotoxicity using complementary in vivo mouse APAP acute liver injury and in vitro hepatocyte-based cytotoxicity readouts. In vivo APAP injury is assessed by serum ALT/AST, liver histology, hepatic glutathione, protein adducts, necrosis, inflammation, and regeneration-related endpoints. In vitro hepatotoxicity is assessed by loss of viability, leakage of ALT/AST/LDH, oxidative-stress markers, mitochondrial function, nuclear morphology, intracellular calcium, and high-content imaging endpoints.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
-
Data Sheet (301 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhou H, et al. Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity. Nature communications. 2021 May 11;12(1):2621. [Content Brief]
[2]. Gu L, et al. A selective Cullin 3 RING E3 ligase inhibitor attenuates hyperglycemia via dual insulin sensitizing and insulinotropic action. bioRxiv [Preprint]. 2026 Feb 1:2026.01.28.702366. [Content Brief]
[3]. Upadhyay KK, et al. The inner nuclear membrane protein SUN1 regulates cullin-3 neddylation to maintain insulin signaling. bioRxiv [Preprint]. 2026 Apr 20:2026.04.16.718478. [Content Brief]
[4]. Zhou Q, et al. The CRL3 ubiquitin ligase-USP18 axis coordinately regulates cystine uptake and ferroptosis by modulating SLC7A11. Proceedings of the National Academy of Sciences of the United States of America. 2024 Jul 09;121(28):e2320655121. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7993 mL | 8.9964 mL | 17.9927 mL | 44.9818 mL |
| 5 mM | 0.3599 mL | 1.7993 mL | 3.5985 mL | 8.9964 mL | |
| 10 mM | 0.1799 mL | 0.8996 mL | 1.7993 mL | 4.4982 mL | |
| 15 mM | 0.1200 mL | 0.5998 mL | 1.1995 mL | 2.9988 mL | |
| 20 mM | 0.0900 mL | 0.4498 mL | 0.8996 mL | 2.2491 mL | |
| 25 mM | 0.0720 mL | 0.3599 mL | 0.7197 mL | 1.7993 mL | |
| 30 mM | 0.0600 mL | 0.2999 mL | 0.5998 mL | 1.4994 mL | |
| 40 mM | 0.0450 mL | 0.2249 mL | 0.4498 mL | 1.1245 mL | |
| 50 mM | 0.0360 mL | 0.1799 mL | 0.3599 mL | 0.8996 mL | |
| 60 mM | 0.0300 mL | 0.1499 mL | 0.2999 mL | 0.7497 mL | |
| 80 mM | 0.0225 mL | 0.1125 mL | 0.2249 mL | 0.5623 mL | |
| 100 mM | 0.0180 mL | 0.0900 mL | 0.1799 mL | 0.4498 mL |